Last reviewed · How we verify
Disorder of blood vessel — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vasodil | TOLAZOLINE | Novartis | tolazoline | Alpha-2A adrenergic receptor | 1948-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Disorder of blood vessel
- Novartis · 1 drug in Disorder of blood vessel
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Disorder of blood vessel:
- Disorder of blood vessel treatment updates — RSS
- Disorder of blood vessel treatment updates — Atom
- Disorder of blood vessel treatment updates — JSON
Cite this brief
Drug Landscape (2026). Disorder of blood vessel — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-of-blood-vessel. Accessed 2026-06-10.
Related
- Disorder of blood vessel full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing